BetterLife Pharma faces civil claim from director Steven Sangha over convertible debenture conversion

Bitget2026/10/09 19:01

BetterLife Pharma faces a civil claim in British Columbia Supreme Court filed Oct. 8, 2026 by independent director Steven Sangha. Dispute centers on repayment of principal on a June 2026 convertible debenture issued to Sangha. Claim seeks an order forcing conversion into 33,333,333 common shares, 33,333,333 share purchase warrants. BetterLife plans to contest the claim. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BetterLife Pharma Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202610091500NEWSFILECNPR____20261009_318380_1) on October 09, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.